---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-095369"
form_type: "8-K"
ticker: "BIOE"
cik: "0001723059"
company_name: "Bio Essence Corp"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:32:57.521876+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bio Essence sells subsidiary BEP for $300K; director Sharon Mair resigns

## Summary
- Sold wholly owned subsidiary Bio Essence Pharmaceutical to Newways, Inc. for $300,000 cash; close expected by Dec 31, 2023.
- Board approved sale on Dec 5, 2023; Stock Purchase Agreement executed Dec 12, 2023.
- Director Sharon Mair resigned from Board effective Dec 8, 2023, with no material dispute reported.

## SEC filing metadata
- accession: 0001213900-23-095369
- form_type: 8-K
- ticker: BIOE
- cik: 0001723059
- company_name: Bio Essence Corp
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723059/000121390023095369/0001213900-23-095369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723059/000121390023095369/ea189979-8k_bioessence.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-095369
- JSON: https://secwatch.observer/filing/0001213900-23-095369.json
- Plain text: https://secwatch.observer/filing/0001213900-23-095369.txt

## Key facts
- Executive change
  Sharon Mair resigned as Director at Bio Essence Corp.
  - Action: resigned
  - Role: Director
  source text: On December 8, 2023, the Company received notice from Sharon Mair, a member of the Company’s Board of Directors, that she resigned from the Board of Directors effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723059/000121390023095369/0001213900-23-095369-index.htm
- Material Agreements
  Bio Essence Corp entered into Stock Purchase Agreement with Newways, Inc. valued at cash consideration in the amount of Three Hundred Thousand Dollars ($300,000) (effective 2023-12-12).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Newways, Inc.
  - Value: cash consideration in the amount of Three Hundred Thousand Dollars ($300,000)
  - Effective: 2023-12-12
  source text: On December 12, 2023, Bio Essence Corp., a California corporation (the “Company”) entered into a Stock Purchase Agreement (“SPA”) with Newways, Inc., a California corporation (“Newways”) whereby the Company agreed to sell to Newways its wholly owned subsidiary, Bio Essence Pharmaceutical, Inc. (“BEP”), in exchange for cash consideration in the amount of Three Hundred Thousand Dollars ($300,000).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723059/000121390023095369/0001213900-23-095369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.